Biopeople

Founder on board

Norway

Founder on board

25.05.2016 - Frode Marc Bohan has been reelected as Chairman of the Board of Directors for Norwegian Vitamin K2 expert NattoPharma ASA. He will continue to chair the board for the next two years.

Bohan founded NattoPharma in 2004. He later founded NoLabel and NutriCon, a nutraceutical and pharmaceutical communications companyl, respectively. Bohan is also a substantial Shareholder of Eqology ASA, and the chairman of the Board of directors at ImmunoPharma AS.

Simultaneously with Bohan’s reelection as chair, the Board of Directors has been extended by two members: Stefan Halldén and Annette Elmqvist.

http://www.european-biotechnology-news.com/people/bio-people/2016/frode-bohan.html

SwedenHungary

23.05.2016 Swedish preeclampsia drug developer A1M Pharma has named Hungarian kidney specialist József Balla as the newest member of its scientific advisory board.

© A1M

Balla has been Director of Operations for Nephrology and Haemodialysis at the University of Debrecen in Hungary since 2003. He has been the principal investigator for clinical studies and is a prolific author. He has also been the recipient of several awards, most recently of the Knight's Cross of the Hungarian Order of Merit.

SwedenUK

17.05.2016 Hansa Medical, a Swedish biopharmaceutical company focusing on novel immunomodulatory enzymes, has appointed Henk Doude van Troostwijk as Vice President, Commercial Operations.

© Hansa Medical

Doude van Troostwijk joins Hansa Medical from Raptor Pharmaceuticals, a US-based orphan drug developer, where he worked as General Manager of European Commercial Operations and Emerging Markets. Previously, he served as Business Unit Director Oncology and Transplantation at Genzyme. 

Doude van Troostwijk holds an MBA from Henley Management College at the University of Reading, UK

BelgiumGermany

06.05.2016 Belgian CRO and service provider Genea has appointed a new Chief Medical Officer. Jörn Balzer will be responsible for the clinical, safety and risk management in Genae’s research services.

© Genea

Balzer, who holds a PhD in Diagnostic Radiology and a Master in Health Business Administration, is head physician and Chief of Department of Radiology and Nuclear Medicine at the Catholic Hospital Mainz, Germany. 

Previously, he was Assistant Medical Director at the Klinikum der Johann Wolfgang Goethe University in Frankfurt am Main, Director at the University Hospital of the Saarland in Homburg /Saar, and Intern at the Charité Campus Virchow Klinikum in Berlin.

SwedenSwitzerland

03.05.2016 Diabetes vaccine developer Diamyd Medical has a new CEO. From now on, Ulf Hannelius will lead the Stockholm-based company.

© Diamyd Medical

Hannelius holds a PhD in molecular biology from the Karolinska Institute and an MBA from the Stockholm School of Economics. Since November 2015, he held the position of Business Development Manager at Diamyd. Prior to that, Hannelius held the same position at Swiss Labtronica SA. In 2011, he founded the life science consultancy provider Aneega AB. As CEO and President, he will focus on building up Diamyd as a “significant” diabetes company. He takes over from Anders Essen-Möller, who was interim CEO.

SwedenUK

27.04.2016 Swedish nanoliter-scale immunoassay pioneer Gyros Protein Technologies, recently established by the merger of Gyros AB and Protein Technologies, Inc., starts expanding into the Asia-Pacific region. Peter Luk takes over as VP Asia-Pacific.

© Gyros Protein Technologies

Luk has over 25 years of life science business experience in Asia. Before joining Gyros Protein Technologies, he was General Manager of ProteinSimple, Asia. Prior to that, Luk was VP Asia-Pacific of Molecular Devices, and he has also held various management roles at PerkinElmer, Packard Biosciences and Bio-Rad Laboratories. He holds an undergraduate degree in Biotechnology from the University of Leeds, UK, and a Master’s degree in Business Administration from the City University of Hong Kong.

DenmarkFinlandNetherlands

25.04.2016 Acesion Pharma’s founding CEO Ulrik Sørensen is moving over for his successor. Seasoned business developer Frans Wuite has been appointed as CEO at the Danish company, which develops first-in-class drugs to treat atrial fibrillation.

© Acesion Pharma

Frans Wuite has more than 25 years pharmaceutical industry experience encompassing leadership roles in start-ups through to large, international companies. Prior to joining Acesion, Wuite led Finnish Oncos Therapeutics, a clinical stage cancer immunotherapy company which successfully merged with Targovax last year. He also led the commercial development and launch of Amgen’s anaemia therapy Aranesp in Europe. Wuite is a board director of Healthcap VII GP S.A. and Herantis Pharma Ltd. He holds an MBA in Business Administration from Tilburg University and an M.D. from the University of Groningen.

Founder Sørensen is taking over as Chief Operating Officer at Acesion.

FranceUKSwitzerland

20.04.2016 Sanofi has appointed Novartis’ ex- Global Head of Medical Affairs Ameet Nathwani as new member of the Executive Committee and Executive VP, Group Chief Medical Officer.

© Sanofi

Nathwani qualified in medicine in 1987 in London and  acquired a specialization in cardiology. He has a diploma in Pharmaceutical Medicine and an executive Masters in Business Administration.

Nathwani started his career in the pharmaceutical industry at Glaxo Group Research in 1994. He held R&D leadership roles in Glaxo, SmithKline Beecham and GlaxoSmithKline, both in Europe and US. From 2004 on, he held a number of positions at Novartis, including Global Development Head of the Cardiovascular and Metabolic Franchise, Global Head of the Critical Care Business Franchise, and Global Head of Medical Affairs.

At Sanofi, Nathwani will be responsible for enterprise-wide medical, patient safety and medical quality. He succeeds Paul Chew, who plans to retire. 

FranceItaly

11.04.2016 French immunotherapy play TxCell has appointed its global Scientific Advisory Board. TChair will be the renowned immunologist Zelig Eshhar, from the Weizmann Institute of science in Rehovot and from the Tel Aviv Sourasky Medical Center in Israel.

© TxCell

Eshhar is widely known for his pioneering research on the Chimeric Antigen Receptor (CAR) approach. He was the first scientist to demonstrate the therapeutic potential of Chimeric Antigen Receptor-engineered Regulatory T (CAR-Treg) cells in models of intestinal inflammation in mice. His achievements have been recognised by several international awards, including the CAR Pioneering award by the ATTACK European Consortium, the Teva and Massry prizes and, most recently, the Israel Prize in Life Sciences.

The first two other members of TxCell’s Scientific Advisory Board will be Professor Chiara Bonini from the San Raffaele Hospital in Milan, Italy, and Doctor Bernard Malissen from Marseille-Luminy Immunology Center in Marseille, France.

EUAustria

02.04.2016 The management board of the European Medicines Agency has elected Christa Wirthumer-Hoche as its chair for the next three years. She has already served as vice-chair of EMA’s Management Board since March 2015.

© BASG - Austrian Federal Office for Safety in Health Care

Wirthumer-Hoche, who holds a doctorate from the Technical University of Vienna and a diploma in chemistry and biochemistry, has headed the Austrian Medicines and Medical Devices Agency since 2013. She is also co-chair of the EU Network Training Centre that was launched in January 2015 and has served as chair of EMA’s Active Substance Master File Working Group.

Wirthumer-Hoche succeeds Sir Kent Woods, who stepped down as chair of the Board in December 2015.

UK

30.03.2016 Cambridge Epigenetix, a developer of epigenetic sequencing technologies, today announced the appointment of Geoff Smith as CEO. Smith joins CEGX from Illumina, where he served most recently as site lead and VP of Product Development.

© Cambridge Epigenetix

Smith worked at Illumina for over 10 years after joining the company via the acquisition of Solexa. Prior to Solexa, he was head of research at Adprotech.

Smith holds a PhD from Cambridge University, and held postdoctoral research positions with HHMI at UT Southwestern, USA and MRC Cambridge, UK.

In conjunction with a US$21m fundraising, Tom Hulme, GV general partner, will join Cambridge Epigenetix’ board of directors and co-founder Bobby Yerramilli-Rao will assume the role of Chairman.

1/35Nächste Seite

Whitepaper

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • BIOTIE THERAPEUTICS (FI)0.27 EUR92.86%
  • PLETHORA (UK)3.38 GBP12.67%
  • 4SC (D)3.25 EUR8.33%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)5.50 SEK-7.56%
  • RENEURON (UK)3.50 GBP-5.41%
  • OXFORD BIOMEDICA (UK)5.62 GBP-4.91%

TOP

  • THERAMETRICS (CH)0.03 CHF50.0%
  • GALAPAGOS (B)52.00 EUR29.9%
  • NICOX (F)10.91 EUR26.6%

FLOP

  • BIONOR PHARMA (N)0.68 NOK-23.6%
  • MOBERG PHARMA (S)38.60 SEK-22.0%
  • BIOCARTIS GROUP NV (B)8.15 EUR-20.1%

TOP

  • CHRONTECH PHARMA (S)0.34 SEK3300.0%
  • KARO BIO (S)31.00 SEK1953.0%
  • NICOX (F)10.91 EUR486.6%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)5.50 SEK-88.8%
  • BB BIOTECH (D)43.82 EUR-84.9%
  • BIOTEST (D)17.14 EUR-77.7%

No liability assumed, Date: 26.05.2016

Events

All Events

Partner-Events

Aachen

Biomedica 2016

Basel (CH)

Chemspec Europe 2016